Sagimet Biosciences Inc. Series A Common Stock - Asset Resilience Ratio
Sagimet Biosciences Inc. Series A Common Stock (SGMT) has an Asset Resilience Ratio of 63.03% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Sagimet Biosciences Inc. Series A Common Stock's Asset Resilience Ratio has changed over time. Check how strategically is Sagimet Biosciences Inc. Series A Common's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Sagimet Biosciences Inc. Series A Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Sagimet Biosciences Inc. Series A Common.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $67.91 Million | 63.03% |
| Total Liquid Assets | $67.91 Million | 63.03% |
Asset Resilience Insights
- Very High Liquidity: Sagimet Biosciences Inc. Series A Common Stock maintains exceptional liquid asset reserves at 63.03% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sagimet Biosciences Inc. Series A Common Stock Industry Peers by Asset Resilience Ratio
Compare Sagimet Biosciences Inc. Series A Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Sagimet Biosciences Inc. Series A Common Stock (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Sagimet Biosciences Inc. Series A Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 67.05% | $78.10 Million | $116.48 Million | +20.00pp |
| 2024-12-31 | 47.06% | $75.41 Million | $160.26 Million | +26.63pp |
| 2023-12-31 | 20.43% | $19.76 Million | $96.72 Million | -77.02pp |
| 2022-12-31 | 97.44% | $32.19 Million | $33.03 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $59.03 Million | -- |
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfun… Read more